异动解读 | 科济药业-B中期业绩改善,股价盘中大涨5.10%

异动解读
Aug 15

科济药业-B(02171.HK)今日盘中大涨5.10%,引起投资者广泛关注。截至发稿时,该股报价为21.96港元,成交额达1640.76万港元。

消息面上,科济药业-B于8月14日公布了2025年中期业绩报告。数据显示,公司期内收益为5096.1万元,同比大幅增长703.8%;毛利达2936.9万元,同比增长约17.16倍。尽管公司仍处于亏损状态,但净亏损已显著收窄至7548.3万元,同比减少78.53%;每股亏损为0.14元。

科济药业-B的这份中期业绩报告展现了公司运营状况的显著改善。收入和毛利的大幅增长表明公司的产品或服务在市场上获得了更多认可。同时,净亏损的大幅收窄也反映出公司在成本控制和运营效率方面取得了进展。公司公告指出,亏损减少主要源于研发开支和行政开支的减少,以及外汇收益净额的上升。这些积极因素共同推动了投资者信心的提升,进而带动股价上涨。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10